Atheneos Ventures

Auxesia Orion specializes in tech-enabled, patient-centric therapeutic management aimed at addressing orphan diseases. The company develops innovative therapeutic solutions that enhance the capabilities of traditional pharmaceuticals, recognizing that medication alone is insufficient for effective treatment. By focusing on the commercialization of advanced technological therapies, Auxesia Orion seeks to provide comprehensive care tailored to the unique needs of patients suffering from rare conditions.

Helios Orion is a corporate strategy advisory firm based in the San Francisco Bay Area that specializes in supporting the growth of innovative healthcare companies across key global markets. The firm collaborates closely with founders and leadership teams to help realize their visions, leveraging a team of seasoned professionals from diverse backgrounds in the healthcare industry. Helios Orion offers a comprehensive range of services, including product development guidance and assistance in enhancing a company's profile, without the need for extensive recruitment of leadership. The firm operates in various global cities, including Santa Clara, Barcelona, Singapore, and Hong Kong, with plans to expand into additional innovation-centric locations. Its focus areas include drugs, diagnostics, medical devices, digital therapeutics, therapeutic foods, AI-based technology, and cross-border collaborations, facilitating connections to the Silicon Valley ecosystem.

Renexxion is a biotechnology company focused on developing naronapride, an oral gastro-prokinetic drug aimed at addressing a significant medical need for patients with functional gastrointestinal disorders. Naronapride belongs to the class of 5-HT4 agonists and is currently in late development, ready for Phase 3 clinical trials. The drug is designed to treat a variety of conditions, including chronic idiopathic constipation, functional dyspepsia, gastroparesis, gastroesophageal reflux disease, Short Bowel Syndrome, enteral feeding intolerance, and post-operative ileus. By developing this innovative treatment, Renexxion aims to provide effective solutions for patients suffering from these challenging gastrointestinal issues.

Armetheon, Inc. is a clinical stage biopharmaceutical company based in the San Francisco Bay area that focuses on developing novel drugs to address significant unmet medical needs. The company is working on several clinical programs, including innovative anticoagulants and antibiotics aimed at treating cardiovascular diseases. One of its key drug candidates is an anti-arrhythmic medication designed for the treatment of ventricular tachycardia in patients with implantable cardioverter defibrillators. This approach enables healthcare providers to offer treatments with improved efficacy, safety, and overall utility for patients suffering from these conditions.

Armetheon, Inc. is a clinical stage biopharmaceutical company based in the San Francisco Bay area that focuses on developing novel drugs to address significant unmet medical needs. The company is working on several clinical programs, including innovative anticoagulants and antibiotics aimed at treating cardiovascular diseases. One of its key drug candidates is an anti-arrhythmic medication designed for the treatment of ventricular tachycardia in patients with implantable cardioverter defibrillators. This approach enables healthcare providers to offer treatments with improved efficacy, safety, and overall utility for patients suffering from these conditions.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.